Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.

Kaipio K, Chen P, Roering P, Huhtinen K, Mikkonen P, Östling P, Lehtinen L, Mansuri N, Korpela T, Potdar S, Hynninen J, Auranen A, Grénman S, Wennerberg K, Hautaniemi S, Carpén O.

J Pathol. 2020 Feb;250(2):159-169. doi: 10.1002/path.5356. Epub 2019 Dec 3.

PMID:
31595974
2.

Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells.

Kettunen K, Boström PJ, Lamminen T, Heinosalo T, West G, Saarinen I, Kaipio K, Rantala J, Albanese C, Poutanen M, Taimen P.

Eur Urol. 2019 Oct;76(4):430-434. doi: 10.1016/j.eururo.2019.06.016. Epub 2019 Jun 28.

3.

Identifying differentially methylated sites in samples with varying tumor purity.

Häkkinen A, Alkodsi A, Facciotto C, Zhang K, Kaipio K, Leppä S, Carpén O, Grénman S, Hynninen J, Hietanen S, Lehtonen R, Hautaniemi S.

Bioinformatics. 2018 Sep 15;34(18):3078-3085. doi: 10.1093/bioinformatics/bty310.

PMID:
29912358
4.

A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.

Tumiati M, Hietanen S, Hynninen J, Pietilä E, Färkkilä A, Kaipio K, Roering P, Huhtinen K, Alkodsi A, Li Y, Lehtonen R, Erkan EP, Tuominen MM, Lehti K, Hautaniemi SK, Vähärautio A, Grénman S, Carpén O, Kauppi L.

Clin Cancer Res. 2018 Sep 15;24(18):4482-4493. doi: 10.1158/1078-0432.CCR-17-3770. Epub 2018 Jun 1.

5.

Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.

Nguyen EV, Huhtinen K, Goo YA, Kaipio K, Andersson N, Rantanen V, Hynninen J, Lahesmaa R, Carpen O, Goodlett DR.

Mol Cell Proteomics. 2017 Jul;16(7):1377-1392. doi: 10.1074/mcp.M116.058321. Epub 2017 Apr 28.

6.

FHOD1 formin is upregulated in melanomas and modifies proliferation and tumor growth.

Peippo M, Gardberg M, Lamminen T, Kaipio K, Carpén O, Heuser VD.

Exp Cell Res. 2017 Jan 1;350(1):267-278. doi: 10.1016/j.yexcr.2016.12.004. Epub 2016 Dec 2.

7.

REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker.

Lehtinen L, Vesterkvist P, Roering P, Korpela T, Hattara L, Kaipio K, Mpindi JP, Hynninen J, Auranen A, Davidson B, Haglund C, Iljin K, Grenman S, Siitari H, Carpen O.

PLoS One. 2016 Mar 16;11(3):e0151590. doi: 10.1371/journal.pone.0151590. eCollection 2016.

8.

Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.

Chen P, Huhtinen K, Kaipio K, Mikkonen P, Aittomäki V, Lindell R, Hynninen J, Auranen A, Grénman S, Lehtonen R, Carpén O, Hautaniemi S.

Cancer Res. 2015 Aug 1;75(15):2987-98. doi: 10.1158/0008-5472.CAN-14-3242. Epub 2015 Jun 29.

9.

Deficiency in Melanocortin 1 Receptor Signaling Predisposes to Vascular Endothelial Dysfunction and Increased Arterial Stiffness in Mice and Humans.

Rinne P, Ahola-Olli A, Nuutinen S, Koskinen E, Kaipio K, Eerola K, Juonala M, Kähönen M, Lehtimäki T, Raitakari OT, Savontaus E.

Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1678-86. doi: 10.1161/ATVBAHA.114.305064. Epub 2015 Apr 30.

PMID:
25931512
10.

FHOD1, a formin upregulated in epithelial-mesenchymal transition, participates in cancer cell migration and invasion.

Gardberg M, Kaipio K, Lehtinen L, Mikkonen P, Heuser VD, Talvinen K, Iljin K, Kampf C, Uhlen M, Grénman R, Koivisto M, Carpén O.

PLoS One. 2013 Sep 26;8(9):e74923. doi: 10.1371/journal.pone.0074923. eCollection 2013.

11.

α-Melanocyte-stimulating hormone regulates vascular NO availability and protects against endothelial dysfunction.

Rinne P, Nordlund W, Heinonen I, Penttinen AM, Saraste A, Ruohonen ST, Mäkelä S, Vähätalo L, Kaipio K, Cai M, Hruby VJ, Ruohonen S, Savontaus E.

Cardiovasc Res. 2013 Feb 1;97(2):360-8. doi: 10.1093/cvr/cvs335. Epub 2012 Nov 5.

12.

Association of the leucine-7 to proline-7 variation in the signal sequence of neuropeptide Y with major depression.

Koefoed P, Woldbye DP, Hansen TV, Eplov LF, Christiansen SH, Mors O, Kessing LV, Werge T, Kaipio K, Pesonen U, Fahmy T, Mellerup E, Jakobsen KD, Hansen ES, Knudsen GM, Bukh JD, Bock C, Lindberg C, Kristensen AS, Dam H, Nordentoft M, Als TD, Wang AG, Gether U, Rehfeld JF, Bolwig TG.

Acta Neuropsychiatr. 2012 Apr;24(2):81-90. doi: 10.1111/j.1601-5215.2011.00600.x.

PMID:
26952950
13.

Characterization of Diaphanous-related formin FMNL2 in human tissues.

Gardberg M, Talvinen K, Kaipio K, Iljin K, Kampf C, Uhlen M, Carpén O.

BMC Cell Biol. 2010 Jul 15;11:55. doi: 10.1186/1471-2121-11-55.

14.

The effect of endogenous preproneuropeptide Y leucine 7 to proline 7 polymorphism on growth and apoptosis in primary cultured HUVECs.

Kaipio K, Kallio J, Pesonen U.

Biol Chem. 2009 Sep;390(9):899-905. doi: 10.1515/BC.2009.097.

PMID:
19558321
15.

The role of non-synonymous NPY gene polymorphism in the nitric oxide production in HUVECs.

Kaipio K, Vahlberg T, Suominen M, Pesonen U.

Biochem Biophys Res Commun. 2009 Apr 17;381(4):587-91. doi: 10.1016/j.bbrc.2009.02.094. Epub 2009 Feb 24.

PMID:
19245788
16.

The intracellular mobility of NPY and a putative mitochondrial form of NPY in neuronal cells.

Kaipio K, Pesonen U.

Neurosci Lett. 2009 Jan 30;450(2):181-5. doi: 10.1016/j.neulet.2008.11.018. Epub 2008 Nov 13.

PMID:
19022345
17.

Transgenic mice overexpressing neuropeptide Y in noradrenergic neurons: a novel model of increased adiposity and impaired glucose tolerance.

Ruohonen ST, Pesonen U, Moritz N, Kaipio K, Röyttä M, Koulu M, Savontaus E.

Diabetes. 2008 Jun;57(6):1517-25. doi: 10.2337/db07-0722. Epub 2008 Feb 14.

18.

Mitochondrial targeting signal in human neuropeptide Y gene.

Kaipio K, Kallio J, Pesonen U.

Biochem Biophys Res Commun. 2005 Nov 18;337(2):633-40. Epub 2005 Sep 23.

PMID:
16199004
19.

Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans.

Kallio J, Pesonen U, Kaipio K, Karvonen MK, Jaakkola U, Heinonen OJ, Uusitupa MI, Koulu M.

FASEB J. 2001 May;15(7):1242-4. No abstract available.

PMID:
11344101

Supplemental Content

Loading ...
Support Center